The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism

Thrombosis and Haemostasis

Volumn 90, Issue 5, 2003, Pages 829-834

  Wells, Philip S ^a,b   Rodger, Marc A ^a,b   Forgie, Melissa A ^a,b   Langlois, Nicole J ^b   Armstrong, Linlea ^c   Carson, Nancy L ^a,c   Jaffey, James ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

ACE; Angiotensin converting enzyme; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ETHNOLOGY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; THROMBOEMBOLISM;

EID: 0242490952     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-03-0170     Document Type: Article

References (31)

1. Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135(5): 367-73.
2. Winkelmann BR, Nauck M, Klein B, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996; 125(1): 19-25.
3. Pawlak R, Chabielska E, Golatowski J, et al. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998; 79: 1208-12.
4. Moulder JE, Fish BL, Cohen EP, et al. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 1996; 146(1): 106-10.
5. Dilley A, Austin H, Hooper WC, et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol 1998; 147(1): 30-5.
6. Gonzalez Ordonez AJ, Fernandez Carreira JM, Medina Rodriguez JM, et al. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis 2000; 11(5): 485-90.
7. Lu Y, Hui R, Zhao Y. Insertion/deletion polymorphism of the angiotensin I converting enzyme gene and pulmonary thromboembolism in Chinese population. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24(5): 265-8.
8. Philipp CS, Dilley A, Saidi P, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 1998; 80: 869-873.
9. Jackson A, Brown K, Langdown J, et al. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Haematol 2000; 111(2): 562-4.
10. Couturaud F, Kearon C. Treatment of deep vein thrombosis. Sem Vasc Med 2002; 1(1): 43-54.
11. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII an effect of von Willebrand factor on occurrence of DVT. Lancet 1995; 345: 152-5.
12. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet 1999; 353: 1167-73.
13. Kamphuisen PW, Eikenboom JCJ, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
14. Bertina RM, Rosendaal FR. Venous thrombosis - The interaction of genes and the environment. N Engl J Med 1998; 338(25): 1840-1.
15. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J of Epidemiol 1996; 143(12): 1257-65.
16. Donnelly JG, Rock GA. Genetic determinants of heritable venous thrombosis: Genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations. Clin Biochem 1999; 32(3): 223-228.
17. Rigat B, Hubert C, Corvol P, et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20(6): 1433.
18. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993; 3(2): 120-1.
19. Ryan DH, Crowther MA, Ginsberg JS, et al. Relation of Factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128(4): 270-6.
20. Kearon C, Gent M, Hirsh J, et al. Extended anticoagulation compared to placebo after three months of therapy for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340(12): 901-7.
21. Stewart GJ, Lachman JW, Alburger PD, et al. Intraoperative venous dilation and subsequent development of deep vein thrombosis in patients undergoing total hip or knee replacement. Ultrasound Med Biol 1990; 16(2): 133-40.
22. Poort SW, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10): 3698-703.
23. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369(6475): 64-7.
24. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86(3): 809-16.
25. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340(12): 901-7.
26. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345(3): 165-9.
27. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of Factor V Leiden mutation. Ann Intern Med 1997; 126(7): 528-31.
28. Zoller B, Berntsdotter A, Garcia de Frutos P, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85(12): 3518-23.
29. Van Boven HH, Vandenbroucke JP, Westendorp RGJ, et al. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77(3): 452-5.
30. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78: 1426-9.
31. Rothman KJ, Greenland S. Case-control studies. In: Rothman KJ, Greenland S, editors. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins, 1998: 93-114.